Assertio Holdings Inc

자세한 내용은 Assertio Holdings Inc 회사

Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

회사 정보

종목 코드 ASRT

회사 이름Assertio Holdings Inc

상장일Feb 12, 1997

CEOMr. Brendan P. O'Grady

직원 수58

유형Ordinary Share

회계 연도 종료Feb 12

주소100 S. Saunders Road

도시LAKE FOREST

증권 거래소NASDAQ Capital Market Consolidated

국가United States of America

우편 번호60045

전화12244197106

웹사이트https://www.assertiotx.com/

종목 코드 ASRT

상장일Feb 12, 1997

CEOMr. Brendan P. O'Grady

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Ajay Patel

Chief Financial Officer, Executive Vice President

196.85K

+12.05%

Mr. Paul Schwichtenberg

Executive Vice President, Chief Transformation Officer

167.52K

+14.47%

Mr. Sam Schlessinger

Executive Vice President, General Counsel

156.13K

+17.33%

Mr. Brendan P. O'Grady

Chief Executive Officer, Director

128.96K

+1001.61%

Mr. David Matthew Stark

Independent Director

107.50K

+100.00%

Mr. William T. Mckee

Independent Director

97.28K

+123.48%

Mr. Mark L Reisenauer

Independent Director

53.75K

--

Ms. Heather L. Mason

Independent Chairman of the Board

--

Mr. Sigurd C. (Sig) Kirk

Independent Director

--

Mr. Sravan K. Emany

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Ajay Patel

Chief Financial Officer, Executive Vice President

196.85K

+12.05%

Mr. Paul Schwichtenberg

Executive Vice President, Chief Transformation Officer

167.52K

+14.47%

Mr. Sam Schlessinger

Executive Vice President, General Counsel

156.13K

+17.33%

Mr. Brendan P. O'Grady

Chief Executive Officer, Director

128.96K

+1001.61%

Mr. David Matthew Stark

Independent Director

107.50K

+100.00%

Mr. William T. Mckee

Independent Director

97.28K

+123.48%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

ROLVEDON

13.12M

49.54%

INDOCIN products

5.54M

20.93%

other

3.56M

13.44%

Sympazan

2.18M

8.23%

SPRIX Nasal Spray

1.59M

6.00%

Royalties and milestone revenue

494.00K

1.86%

지역별USD

이름

수익

비율

United States

26.49M

100.00%

사업별

지역별

사업별USD

이름

수익

비율

ROLVEDON

13.12M

49.54%

INDOCIN products

5.54M

20.93%

other

3.56M

13.44%

Sympazan

2.18M

8.23%

SPRIX Nasal Spray

1.59M

6.00%

Royalties and milestone revenue

494.00K

1.86%

주식 보유 통계

마지막 업데이트: Fri, May 16

주주

주주 유형

주주

비율

Nantahala Capital Management, LLC

8.81%

The Vanguard Group, Inc.

4.58%

Renaissance Technologies LLC

2.82%

BlackRock Institutional Trust Company, N.A.

1.45%

Two Sigma Investments, LP

1.28%

Other

81.06%

주주

비율

Nantahala Capital Management, LLC

8.81%

The Vanguard Group, Inc.

4.58%

Renaissance Technologies LLC

2.82%

BlackRock Institutional Trust Company, N.A.

1.45%

Two Sigma Investments, LP

1.28%

Other

81.06%

주주 유형

주주

비율

Hedge Fund

13.93%

Investment Advisor

9.29%

Investment Advisor/Hedge Fund

3.63%

Individual Investor

2.63%

Research Firm

0.15%

Other

70.37%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

311

28.39M

29.65%

-30.82M

2025Q1

337

28.16M

29.40%

-32.55M

2024Q4

339

31.00M

32.47%

-30.41M

2024Q3

330

33.06M

34.86%

-33.72M

2024Q2

326

40.98M

43.17%

-33.17M

2024Q1

316

48.96M

52.78%

-20.37M

2023Q4

308

49.49M

53.68%

-10.26M

2023Q3

295

49.25M

53.86%

+8.83M

2023Q2

258

36.71M

65.25%

+1.46M

2023Q1

203

27.95M

50.57%

+2.57M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Nantahala Capital Management, LLC

8.44M

8.81%

+291.43K

+3.58%

Mar 31, 2025

The Vanguard Group, Inc.

4.38M

4.58%

--

Mar 31, 2025

Renaissance Technologies LLC

2.70M

2.82%

-289.05K

-9.66%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

1.39M

1.45%

-13.17K

-0.94%

Mar 31, 2025

Two Sigma Investments, LP

1.23M

1.28%

-401.09K

-24.66%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.11M

1.16%

+11.78K

+1.08%

Mar 31, 2025

Millennium Management LLC

784.58K

0.82%

-316.70K

-28.76%

Mar 31, 2025

Polen Capital Management, LLC

424.06K

0.44%

-227.56K

-34.92%

Nov 30, 2024

AQR Capital Management, LLC

636.77K

0.66%

-265.80K

-29.45%

Mar 31, 2025

Peisert (Daniel A)

607.46K

0.63%

--

Mar 13, 2025

0.713USD

Assertio Holdings Inc

0.713

개요

회사

금융